Le priorità associate all'uso dei farmaci "off-label": Il punto di vista del pediatra ospedaliero

Translated title of the contribution: Priorities among off-label prescriptions: Paediatricians' perspective

Federico Marchetti, J. Bua, S. Demarini, R. Devescovi, C. Germani, P. Mergoni, G. Messi, M. Pennesi, M. Rabusin, A. Sarti, A. Ventura, A. Arrighini, G. Chirico, M. Duse, N. Miguetti, M. S. Molinaro, L. D. Notarangelo, F. Porta, V. Porteri, E. SonciniR. F. Schumacher, S. Di Maio, L. Di Martino, L. Giordano, F. De Leva, C. Pecoraro, M. Baldi, E. Banaudi, S. Einaudi, G. Migliore, P. Pecco, P. Saracco, A. Tocchet, M. Bonati

Research output: Contribution to journalArticle

Abstract

Two thirds of the drugs prescribed for children are off-label. However, off-label is not synonymous with incorrect, since it often represents the most rational, evidence-based therapy. Existing data on the use of off-label in children are based on prescriptions registers. The aim of our study was to investigate the paediatricians' perspective on off-label use in their everyday hospital practice. Four Paediatrics Italian Hospitals were involved in the study. Questionnaires covered eight different department/speciality units. Our findings showed that the most common reasons detected for off-label use were formulation and age. Corticosteroids, antihypertensive drugs and midazolam were most frequently indicated as off-label for formulation, while ciprofloxacin, new generation anti-epilepsy drugs (lamotrigine, oxcarbazepine) and immunosuppressant (mycophenolate, rituximab) for age. The drugs identified as off-label differed according to department, although some recurred (i.e. ACE inhibitors, ketorolac). Our survey might be of help for planning appropriate interventions to tackle the problem of off-label use in paediatrics.

Original languageItalian
Pages (from-to)527-531
Number of pages5
JournalMedico e Bambino
Volume24
Issue number8
Publication statusPublished - Oct 31 2005

Fingerprint

Off-Label Use
Prescriptions
Pharmaceutical Preparations
Ketorolac
Pediatric Hospitals
Midazolam
Immunosuppressive Agents
Ciprofloxacin
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Epilepsy
Adrenal Cortex Hormones
Pediatrics
Pediatricians
Surveys and Questionnaires

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Le priorità associate all'uso dei farmaci "off-label" : Il punto di vista del pediatra ospedaliero. / Marchetti, Federico; Bua, J.; Demarini, S.; Devescovi, R.; Germani, C.; Mergoni, P.; Messi, G.; Pennesi, M.; Rabusin, M.; Sarti, A.; Ventura, A.; Arrighini, A.; Chirico, G.; Duse, M.; Miguetti, N.; Molinaro, M. S.; Notarangelo, L. D.; Porta, F.; Porteri, V.; Soncini, E.; Schumacher, R. F.; Di Maio, S.; Di Martino, L.; Giordano, L.; De Leva, F.; Pecoraro, C.; Baldi, M.; Banaudi, E.; Einaudi, S.; Migliore, G.; Pecco, P.; Saracco, P.; Tocchet, A.; Bonati, M.

In: Medico e Bambino, Vol. 24, No. 8, 31.10.2005, p. 527-531.

Research output: Contribution to journalArticle

Marchetti, F, Bua, J, Demarini, S, Devescovi, R, Germani, C, Mergoni, P, Messi, G, Pennesi, M, Rabusin, M, Sarti, A, Ventura, A, Arrighini, A, Chirico, G, Duse, M, Miguetti, N, Molinaro, MS, Notarangelo, LD, Porta, F, Porteri, V, Soncini, E, Schumacher, RF, Di Maio, S, Di Martino, L, Giordano, L, De Leva, F, Pecoraro, C, Baldi, M, Banaudi, E, Einaudi, S, Migliore, G, Pecco, P, Saracco, P, Tocchet, A & Bonati, M 2005, 'Le priorità associate all'uso dei farmaci "off-label": Il punto di vista del pediatra ospedaliero', Medico e Bambino, vol. 24, no. 8, pp. 527-531.
Marchetti, Federico ; Bua, J. ; Demarini, S. ; Devescovi, R. ; Germani, C. ; Mergoni, P. ; Messi, G. ; Pennesi, M. ; Rabusin, M. ; Sarti, A. ; Ventura, A. ; Arrighini, A. ; Chirico, G. ; Duse, M. ; Miguetti, N. ; Molinaro, M. S. ; Notarangelo, L. D. ; Porta, F. ; Porteri, V. ; Soncini, E. ; Schumacher, R. F. ; Di Maio, S. ; Di Martino, L. ; Giordano, L. ; De Leva, F. ; Pecoraro, C. ; Baldi, M. ; Banaudi, E. ; Einaudi, S. ; Migliore, G. ; Pecco, P. ; Saracco, P. ; Tocchet, A. ; Bonati, M. / Le priorità associate all'uso dei farmaci "off-label" : Il punto di vista del pediatra ospedaliero. In: Medico e Bambino. 2005 ; Vol. 24, No. 8. pp. 527-531.
@article{b7d439b723e144c5925fa92a5ad5fb61,
title = "Le priorit{\`a} associate all'uso dei farmaci {"}off-label{"}: Il punto di vista del pediatra ospedaliero",
abstract = "Two thirds of the drugs prescribed for children are off-label. However, off-label is not synonymous with incorrect, since it often represents the most rational, evidence-based therapy. Existing data on the use of off-label in children are based on prescriptions registers. The aim of our study was to investigate the paediatricians' perspective on off-label use in their everyday hospital practice. Four Paediatrics Italian Hospitals were involved in the study. Questionnaires covered eight different department/speciality units. Our findings showed that the most common reasons detected for off-label use were formulation and age. Corticosteroids, antihypertensive drugs and midazolam were most frequently indicated as off-label for formulation, while ciprofloxacin, new generation anti-epilepsy drugs (lamotrigine, oxcarbazepine) and immunosuppressant (mycophenolate, rituximab) for age. The drugs identified as off-label differed according to department, although some recurred (i.e. ACE inhibitors, ketorolac). Our survey might be of help for planning appropriate interventions to tackle the problem of off-label use in paediatrics.",
keywords = "Children, Hospital-based survey, Off-label drugs",
author = "Federico Marchetti and J. Bua and S. Demarini and R. Devescovi and C. Germani and P. Mergoni and G. Messi and M. Pennesi and M. Rabusin and A. Sarti and A. Ventura and A. Arrighini and G. Chirico and M. Duse and N. Miguetti and Molinaro, {M. S.} and Notarangelo, {L. D.} and F. Porta and V. Porteri and E. Soncini and Schumacher, {R. F.} and {Di Maio}, S. and {Di Martino}, L. and L. Giordano and {De Leva}, F. and C. Pecoraro and M. Baldi and E. Banaudi and S. Einaudi and G. Migliore and P. Pecco and P. Saracco and A. Tocchet and M. Bonati",
year = "2005",
month = "10",
day = "31",
language = "Italian",
volume = "24",
pages = "527--531",
journal = "Medico e Bambino",
issn = "1591-3090",
publisher = "Medico e Bambino",
number = "8",

}

TY - JOUR

T1 - Le priorità associate all'uso dei farmaci "off-label"

T2 - Il punto di vista del pediatra ospedaliero

AU - Marchetti, Federico

AU - Bua, J.

AU - Demarini, S.

AU - Devescovi, R.

AU - Germani, C.

AU - Mergoni, P.

AU - Messi, G.

AU - Pennesi, M.

AU - Rabusin, M.

AU - Sarti, A.

AU - Ventura, A.

AU - Arrighini, A.

AU - Chirico, G.

AU - Duse, M.

AU - Miguetti, N.

AU - Molinaro, M. S.

AU - Notarangelo, L. D.

AU - Porta, F.

AU - Porteri, V.

AU - Soncini, E.

AU - Schumacher, R. F.

AU - Di Maio, S.

AU - Di Martino, L.

AU - Giordano, L.

AU - De Leva, F.

AU - Pecoraro, C.

AU - Baldi, M.

AU - Banaudi, E.

AU - Einaudi, S.

AU - Migliore, G.

AU - Pecco, P.

AU - Saracco, P.

AU - Tocchet, A.

AU - Bonati, M.

PY - 2005/10/31

Y1 - 2005/10/31

N2 - Two thirds of the drugs prescribed for children are off-label. However, off-label is not synonymous with incorrect, since it often represents the most rational, evidence-based therapy. Existing data on the use of off-label in children are based on prescriptions registers. The aim of our study was to investigate the paediatricians' perspective on off-label use in their everyday hospital practice. Four Paediatrics Italian Hospitals were involved in the study. Questionnaires covered eight different department/speciality units. Our findings showed that the most common reasons detected for off-label use were formulation and age. Corticosteroids, antihypertensive drugs and midazolam were most frequently indicated as off-label for formulation, while ciprofloxacin, new generation anti-epilepsy drugs (lamotrigine, oxcarbazepine) and immunosuppressant (mycophenolate, rituximab) for age. The drugs identified as off-label differed according to department, although some recurred (i.e. ACE inhibitors, ketorolac). Our survey might be of help for planning appropriate interventions to tackle the problem of off-label use in paediatrics.

AB - Two thirds of the drugs prescribed for children are off-label. However, off-label is not synonymous with incorrect, since it often represents the most rational, evidence-based therapy. Existing data on the use of off-label in children are based on prescriptions registers. The aim of our study was to investigate the paediatricians' perspective on off-label use in their everyday hospital practice. Four Paediatrics Italian Hospitals were involved in the study. Questionnaires covered eight different department/speciality units. Our findings showed that the most common reasons detected for off-label use were formulation and age. Corticosteroids, antihypertensive drugs and midazolam were most frequently indicated as off-label for formulation, while ciprofloxacin, new generation anti-epilepsy drugs (lamotrigine, oxcarbazepine) and immunosuppressant (mycophenolate, rituximab) for age. The drugs identified as off-label differed according to department, although some recurred (i.e. ACE inhibitors, ketorolac). Our survey might be of help for planning appropriate interventions to tackle the problem of off-label use in paediatrics.

KW - Children

KW - Hospital-based survey

KW - Off-label drugs

UR - http://www.scopus.com/inward/record.url?scp=28144452313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28144452313&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:28144452313

VL - 24

SP - 527

EP - 531

JO - Medico e Bambino

JF - Medico e Bambino

SN - 1591-3090

IS - 8

ER -